Daniel Morgenstern: Selpercatinib Shows Impressive Response and Disease Control Rates in Rare Pediatric Cancers
Daniel Morgenstern, a staff physician at The Hospital for Sick Children, highlighted the success of selpercatinib, a RET inhibitor developed by Loxo Oncology (acquired by Eli Lilly), in treating rare pediatric cancers. The drug showed impressive response and disease control rates in a pediatric phase I/II study published in the Journal of Clinical Oncology. Morgenstern emphasized the need for similar targeted treatments for other pediatric cancers.
How this was made
The 30-second read
Why it matters
The data highlights a new therapeutic option for rare pediatric cancers, potentially expanding Lilly's oncology portfolio and market valuation.
Market read
First‑time disclosure of positive pediatric trial data for a Lilly‑owned drug, likely to influence biotech sentiment and stock movement.
What to watch
Regulatory timeline and potential competition from other RET inhibitors could temper upside.
Background
Eli Lilly (via its acquisition of Loxo Oncology) announced first pediatric efficacy results for selpercatinib, a RET inhibitor, in the Journal of Clinical Oncology.
Ticker impact
Phase I/II pediatric study of selpercatinib shows impressive response and disease control rates.
potential upside as market prices in the favorable clinical results
First disclosure of pediatric efficacy data for a RET inhibitor; biotech stocks typically react positively to early‑stage success.
Market effects
strengthens confidence in pediatric oncology pipelines and may lift peer biotech stocks focused on targeted therapies.
minimal regional effect; impact confined to US biotech sector.
adds to global interest in RET‑targeted drugs and could influence international investors tracking oncology breakthroughs.
Counterpoint
Data is early‑stage; efficacy may not translate to later phases, so price reaction could be muted.
Key entities
- CompanyEli Lilly
Pharmaceutical company that acquired Loxo Oncology and develops selpercatinib.
- DrugSelpercatinib
RET inhibitor showing strong pediatric trial results.
